107 related articles for article (PubMed ID: 15269785)
1. A clinical and pharmacological study of arsenic trioxide in advanced multiple myeloma patients.
Rousselot P; Larghero J; Arnulf B; Poupon J; Royer B; Tibi A; Madelaine-Chambrin I; Cimerman P; Chevret S; Hermine O; Dombret H; Claude Brouet J; Paul Fermand J
Leukemia; 2004 Sep; 18(9):1518-21. PubMed ID: 15269785
[TBL] [Abstract][Full Text] [Related]
2. Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma.
Hussein MA; Saleh M; Ravandi F; Mason J; Rifkin RM; Ellison R
Br J Haematol; 2004 May; 125(4):470-6. PubMed ID: 15142117
[TBL] [Abstract][Full Text] [Related]
3. Clinical activity of arsenic trioxide for the treatment of multiple myeloma.
Munshi NC; Tricot G; Desikan R; Badros A; Zangari M; Toor A; Morris C; Anaissie E; Barlogie B
Leukemia; 2002 Sep; 16(9):1835-7. PubMed ID: 12200700
[TBL] [Abstract][Full Text] [Related]
4. Arsenic trioxide in patients with refractory multiple myeloma: a prospective, phase II, single-arm study.
Sanaat Z; Rezazadeh M; Gharamaleki JV; Ziae JE; Esfahani A
Acta Med Iran; 2011; 49(8):504-8. PubMed ID: 22009804
[TBL] [Abstract][Full Text] [Related]
5. Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes.
Schiller GJ; Slack J; Hainsworth JD; Mason J; Saleh M; Rizzieri D; Douer D; List AF
J Clin Oncol; 2006 Jun; 24(16):2456-64. PubMed ID: 16651647
[TBL] [Abstract][Full Text] [Related]
6. Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience.
Lazo G; Kantarjian H; Estey E; Thomas D; O'Brien S; Cortes J
Cancer; 2003 May; 97(9):2218-24. PubMed ID: 12712474
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study.
Berenson JR; Boccia R; Siegel D; Bozdech M; Bessudo A; Stadtmauer E; Talisman Pomeroy J; Steis R; Flam M; Lutzky J; Jilani S; Volk J; Wong SF; Moss R; Patel R; Ferretti D; Russell K; Louie R; Yeh HS; Swift RA
Br J Haematol; 2006 Oct; 135(2):174-83. PubMed ID: 17010047
[TBL] [Abstract][Full Text] [Related]
8. Arsenic trioxide is effective in the treatment of multiple myeloma in SCID mice.
Rousselot P; Larghero J; Labaume S; Poupon J; Chopin M; Dosquet C; Marolleau JP; Janin A; Brouet JC; Fermand JP
Eur J Haematol; 2004 Mar; 72(3):166-71. PubMed ID: 14962234
[TBL] [Abstract][Full Text] [Related]
9. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.
Thirugnanam R; George B; Chendamarai E; Lakshmi KM; Balasubramanian P; Viswabandya A; Srivastava A; Chandy M; Mathews V
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1479-84. PubMed ID: 19822309
[TBL] [Abstract][Full Text] [Related]
10. Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study.
Vey N; Bosly A; Guerci A; Feremans W; Dombret H; Dreyfus F; Bowen D; Burnett A; Dennis M; Ribrag V; Casadevall N; Legros L; Fenaux P
J Clin Oncol; 2006 Jun; 24(16):2465-71. PubMed ID: 16651646
[TBL] [Abstract][Full Text] [Related]
11. Arsenic trioxide: expanding roles for an ancient drug?
Ravandi F
Leukemia; 2004 Sep; 18(9):1457-9. PubMed ID: 15269784
[No Abstract] [Full Text] [Related]
12. The efficacy of arsenic trioxide for the treatment of relapsed and refractory multiple myeloma: a systematic review.
Röllig C; Illmer T
Cancer Treat Rev; 2009 Aug; 35(5):425-30. PubMed ID: 19464807
[TBL] [Abstract][Full Text] [Related]
13. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data.
Mathews V; George B; Chendamarai E; Lakshmi KM; Desire S; Balasubramanian P; Viswabandya A; Thirugnanam R; Abraham A; Shaji RV; Srivastava A; Chandy M
J Clin Oncol; 2010 Aug; 28(24):3866-71. PubMed ID: 20644086
[TBL] [Abstract][Full Text] [Related]
14. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: a bridge to transplantation.
Leoni F; Gianfaldoni G; Annunziata M; Fanci R; Ciolli S; Nozzoli C; Ferrara F
Haematologica; 2002 May; 87(5):485-9. PubMed ID: 12010661
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of arsenic trioxide for patients with advanced metastatic melanoma.
Tarhini AA; Kirkwood JM; Tawbi H; Gooding WE; Islam MF; Agarwala SS
Cancer; 2008 Mar; 112(5):1131-8. PubMed ID: 18286511
[TBL] [Abstract][Full Text] [Related]
16. A patient with progressive multiple myeloma treated successfully with arsenic trioxide after allogeneic bone marrow transplantation.
Gesundheit B; Shapira MY; Ackerstein A; Resnik IB; Bitan M; Or R
Acta Haematol; 2007; 117(2):119-21. PubMed ID: 17135719
[TBL] [Abstract][Full Text] [Related]
17. Phase II clinical trial of arsenic trioxide with liposomal doxorubicin, vincristine, and dexamethasone in newly diagnosed multiple myeloma.
Hofmeister CC; Jansak B; Denlinger N; Kraut EH; Benson DM; Farag SS
Leuk Res; 2008 Aug; 32(8):1295-8. PubMed ID: 18082257
[TBL] [Abstract][Full Text] [Related]
18. A phase II trial of arsenic trioxide in patients with metastatic melanoma.
Kim KB; Bedikian AY; Camacho LH; Papadopoulos NE; McCullough C
Cancer; 2005 Oct; 104(8):1687-92. PubMed ID: 16130126
[TBL] [Abstract][Full Text] [Related]
19. A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma.
Berenson JR; Matous J; Swift RA; Mapes R; Morrison B; Yeh HS
Clin Cancer Res; 2007 Mar; 13(6):1762-8. PubMed ID: 17363530
[TBL] [Abstract][Full Text] [Related]
20. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas.
Bremer K
J Cancer Res Clin Oncol; 2002 Nov; 128(11):603-9. PubMed ID: 12458340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
